Examining how sodium intake affects spondyloarthritis
Official title: Sodium Intake in spondyLoarthriTes: Analysis of the Influence on the Activity of the Disease and the Therapeutic Response to Anti IL-17A Agents.
Run by Centre Hospitalier Universitaire de Besancon · NCT06259890 · Data updated 2026-11-12
This study is testing how changing salt intake might affect the symptoms of people with spondyloarthritis or psoriatic arthritis.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Besancon Academic / other |
| Drugs / interventions | secukinumab, ixekizumab, bimekizumab, brodalumab, ustekinumab, guselkumab, risankizumab, tildrakizumab, prednisone |
| Locations | 4 sites (Besançon and 3 other locations) |
| Status | Recruiting |
| Started | January 30, 2024 |
| Main results expected | November 2026 |
| Study ends | May 2027 |
| Registry record updated | July 9, 2025 |
| Trial ID | NCT06259890 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include women who are menopausal or surgically sterilized, or women of childbearing potential using effective contraception, who have axial spondyloarthritis or psoriatic arthritis.
✕Probably not a fit
Patients currently treated with specific immunosuppressive therapies or systemic corticosteroids may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The SALT study aims to investigate the relationship between dietary sodium intake and disease activity in patients diagnosed with axial spondyloarthritis (both radiographic and non-radiographic) or psoriatic arthritis. Participants will have their salt intake measured to assess its influence on their condition. This interventional approach seeks to provide insights into dietary modifications that could potentially improve patient outcomes.
Why it matters
Potential benefit: If successful, this study could lead to dietary recommendations that help manage disease activity in patients with spondyloarthritis.
How similar studies have gone: While the relationship between sodium intake and arthritis has been explored, this specific approach is relatively novel and has not been extensively tested in similar studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with axial spondyloarthritis (radiographic or non-radiographic) or psoriatic arthritis * women who have been menopausal for at least 24 months, surgically sterilized, or, for women of childbearing potentiale, use an effective method of contraception (oral contraceptives, contraceptive injections, intrauterine devices, double-barrier method, contraceptive patches) Exclusion Criteria: * patient treated by cyclosporine, diuretics, angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists. * current treatment with an anti-IL-17A agent (secukinumab or ixekizumab or bimekizumab or brodalumab) or with an anti-IL23 agent (ustekinumab, guselkumab, risankizumab or tildrakizumab) or previous treatment less than 6 months old. * patients on systemic corticosteroids with corticosteroid therapy \> 10 mg prednisone equivalent * pregnant woman
Where it's running
-
CHU Besançon
Besançon, France Recruiting -
CHD Vendée
La Roche-sur-Yon, France Recruiting -
CHU St Etienne
Saint-Etienne, France Recruiting -
Hôpital Nord Franche-Comté
Trévenans, France Recruiting
Study contacts
- Study coordinator: Guillaume BOITEUX, PhD
- Email: gboiteux@chu-besancon.fr
- Phone: +33381218957
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Guselkumab in Breast Milk for Lactating Women on Guselkumab
This study tests how much guselkumab is present in the breast milk of lactating women who are already receiving guselkumab for their approved conditions.
-
One-year guselkumab use in adults with psoriatic arthritis
This project will see how long adults with psoriatic arthritis stay on guselkumab over one year when prescribed as part of routine care.
-
Guselkumab for people with psoriatic arthritis in routine care
This study will test whether guselkumab given in routine clinical care reduces joint inflammation in people with psoriatic arthritis using musculoskeletal ultrasound to track changes.
-
Guselkumab treatment for psoriatic arthritis in Indian participants
This tests whether guselkumab injections are safe and can help Indian patients with psoriatic arthritis who have not improved with standard treatments.
-
Effects of phytocannabinoids on immune response in chronic inflammatory diseases
This study is testing whether phytocannabinoids like CBD and THC can help improve the immune response in people with chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.
-
Understanding pain in inflammatory joint diseases
This project will follow people with inflammatory joint diseases who are starting or switching biological or targeted synthetic DMARDs to try to identify different pain types and see if central sensitization and cognitive function relate to persistent pain.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.